Crispr announces updates across in vivo cardiovascular disease progams

CRISPR Therapeutics (CRSP) announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310, targeting ANGPTL3, as well as continued progress on CTX320, targeting the LPA gene, and CTX340, targeting the AGT gene. CTX310, targeting ANGPTL3: CTX310 is in an ongoing Phase 1 first-in-human clinical trial targeting ANGPTL3 in four patient groups. These new results build upon previously disclosed results from the first 10 patients across the first four cohorts. The Company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025. CTX320, targeting LPA: CTX320 is in an ongoing Phase 1 clinical trial targeting the LPA gene in patients with elevated lipoprotein. The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp landscape. CTX340, targeting angiotensinogen, AGT: CRISPR Therapeutics is also advancing its preclinical in vivo cardiovascular program CTX340, targeting angiotensinogen for the treatment of refractory hypertension. CTX340 is currently progressing through IND/CTA-enabling studies.